Received grant in 2020
DCCC has funded 200,000 DKK to the project.
The primary purpose of the present phase III randomized follow-up trial is for the first time to investigate if circulating tumor DNA (i.e. pHPV blood test) can improve the detection of early treatment failure or recurrence and hereby assist in increasing the potential for cure.
Secondly we aim to provide evidence for use of imaging and thirdly, to establish early interventions against late morbidities. This trial compares standard of care (SOC) FU and pHPV guided follow-up after standard curative chemoradiation for anal cancer in 400 patients from 10 Nordic centers.
Multidisciplinary organisation
DACG, DCCC-RT & DCCC-ctDNA center
Project stakeholders
Danish Anal Cancer Group
- Karen-Lise Garm Spindler, MD, Phd., DMSc, Chair DACG, Aarhus University Hospital. Primary contact, Mail: k.g.spindler@rm.dk
- Eva Serup-Hansen, Dept. of Oncology, Herlev
- Birgitte Havelund, Dept. of Oncology, Vejle
- Niels Pallisgard, Zealand University Hospital
Trial Management Group
- Investigator, Danish national Personal Identification Number
- Anders Johnsson, Swedish national Personal Identification Number
- Marianne Guren, Norwegian national Personal Identification Number
- Pia Østerlund, Finnish national Personal Identification Number
- Annika Ålgar, Finnish national Personal Identification Number
External review board
- Anders Jakobsen, Vejle, DK
- Bengt Glimelius, Stockholm, SE
- Olav Dahl, Bergen, NO